Welcome to our dedicated page for Regulus Therapeutics news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeutics stock.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is a pioneering biopharmaceutical company dedicated to discovering and developing novel medicines that target microRNAs. With a strong foundation in oligonucleotide drug discovery and development, Regulus has established a comprehensive pipeline of microRNA-based therapeutics and an advanced biomarkers platform known as MicroMarkersSM. The company’s intellectual property estate further solidifies its leadership in the microRNA field.
Regulus is at the forefront of developing innovative treatments for critical health issues. One of its significant projects includes RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 aimed at treating chronic hepatitis C virus infection. Another promising drug candidate is RG-012, which targets microRNA-21 for treating Alport Syndrome, a severe kidney disease driven by genetic mutations with no approved therapies currently available.
Moreover, Regulus, in collaboration with AstraZeneca, is working on RG-125, an anti-miR targeting microRNA-103/107 for treating non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes/pre-diabetes, which has already entered Phase I clinical development. Additionally, RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17, is in Phase 1b clinical development for treating autosomal dominant polycystic kidney disease (ADPKD).
Recently, Regulus reported positive topline data from the first and second cohorts of the Phase 1b MAD study of RGLS8429. The company has completed enrollment for the third cohort of this study, with topline data expected in mid-2024. The latest updates indicate the initiation of the fourth cohort in May 2024, focusing on a fixed dose of 300 mg of RGLS8429, which will provide further insights into its efficacy and safety.
Financially, Regulus is in a stable position, having recently raised $100 million through a private placement to institutional investors, extending its cash runway until the first half of 2026. For the quarter ended March 31, 2024, the company reported $107.7 million in cash and investments.
Regulus is committed to advancing its pipeline and bringing life-changing therapeutics to patients, with a particular focus on orphan kidney diseases. The company’s strategic collaborations and solid financial base are instrumental in driving its innovative research and development initiatives.
Regulus Therapeutics Inc. announced the advancement to cohort 4 of the Phase 1b Clinical Trial of RGLS8429 for the treatment of ADPKD. The study will evaluate the safety, efficacy, and impact on total kidney volume in patients with this disease. Positive data from previous cohorts has paved the way for this advancement, with potential for a pivotal Phase 2 trial. The trial aims to assess changes in urinary polycystins, kidney volume, cyst architecture, and overall kidney function.
Regulus Therapeutics Inc. will participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series, with CEO Jay Hagan and President Preston Klassen, M.D. The event, hosted by Whitney Ijem on May 1, 2024, at 1:00 p.m. ET, will be live and available for replay on the company's investor relations website for 90 days.
FAQ
What is the current stock price of Regulus Therapeutics (RGLS)?
What is the market cap of Regulus Therapeutics (RGLS)?
What is Regulus Therapeutics Inc. known for?
What are the main projects of Regulus Therapeutics?
What is RG-101 used for?
What stage is the clinical development of RGLS8429?
Who are Regulus Therapeutics' strategic partners?
What is the financial status of Regulus Therapeutics?
What recent achievements has Regulus Therapeutics reported?
Where is Regulus Therapeutics headquartered?
What is the focus of Regulus Therapeutics' RGLS8429 program?
How does Regulus Therapeutics intend to use the funds raised in the private placement?
